EMERGING PHARMACEUTICAL COMPANY | HarborSide Associate

EMERGING PHARMACEUTICAL COMPANY: NOVEL INSULIN PRODUCT POSITIONING & MARKET FORECAST

Novel Oral Insulin Product - Conducted research that identified a larger market opportunity that could be realized by repositioning the product clinically while enhancing the value proposition through critical changes to the Phase III trial design.

CHALLENGE:

The company was about to enter phase III trials and wanted to understand the market opportunity and how to segment & position the product to maximize adoption. Previous research had indicated this was a niche product with a relatively small market opportunity.

SOLUTION:

Conducted research that identified a larger market opportunity that could be realized by repositioning the product clinically while enhancing the value proposition through critical changes to the Phase III trial design.

PROCESS:

Conducted Research: Utilized Seagrove proprietary database to recruit clinicians, patients & top payers to conduct a series of focus groups.

Developed Insights: Based on the research and the team's deep diabetes expertise, identified a larger opportunity, new positioning, and Phase III trial recommendations.

Modeled Market Adoption: Developed customized market model to project adoption based on new positioning & segmentation as well as the results of the Phase III trial.